Upregulation of NKG2C + Natural Killer Cells,TLR-2 Expression on Monocytes and Downregulation of Regulatory T-Cells Influence PEG-IFN Treatment Efficacy in Entecavir-Suppressed Patients with CHB
Free accessResearch articleFirst published online August, 2015
Upregulation of NKG2C + Natural Killer Cells,TLR-2 Expression on Monocytes and Downregulation of Regulatory T-Cells Influence PEG-IFN Treatment Efficacy in Entecavir-Suppressed Patients with CHB
There is increasing evidence that host immune responses influence antiviral efficacy in chronic hepatitis B (CHB). The aim of this study was to characterize the immunological features responsible for improved treatment responses with pegylated interferon (PEG-IFN)-α2a in entecavir (ETV)-suppressed patients with CHB.
Methods
Peripheral natural killer (NK) cells, Toll-like receptors (TLRs), T-cell subsets, regulatory T-cells (Tregs) and programmed death 1 (PD-1) were evaluated dynamically in 77 patients undergoing a clinical trial (OSST trial, NCT00940485) by flow cytometry. Response was defined as hepatitis B e antigen (HBeAg) seroconversion, hepatitis B surface antigen (HBsAg) loss and HBsAg seroconversion (either as singular events or in combination at week 48).
Results
Compared with ETV responders or PEG-IFN-α non-responders, PEG-IFN-α responders exhibited a significant decline in HBsAg during treatment (P=0.033 and P<0.001, respectively) and a significant decline in Treg proportions from week 12 to week 24 (P=0.036 and P=0.004, respectively). Moreover, PEG-IFN-α responders showed a significantly higher increase in the NKG2C+ NK cell proportions from baseline to week 12 (P=0.0073) and of TLR2+ monocytes at week 12 than PEG-IFN-α non-responders (P=0.039).
Conclusions
Successful response to PEG-IFN-α correlates with an early significant restoration of impaired immune responses. Although antiviral treatment response can be achieved by both IFN and ETV, the underlying immunological features vary which may explain the generally observed difference in off-treatment durability of response between the two treatments, as well as effects on HBsAg.
References
1.
AyoubW.S., KeeffeE.B.Review article: current antiviral therapy of chronic hepatitis B.Aliment Pharmacol Ther2011; 34: 1145–1158.
2.
European Association for the Study of the Liver.EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection.J Hepatol2012; 57: 167–185.
3.
NingQ., HanM., SunY.Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomised open-label trial (OSST trial).J Hepatol2014; 61: 777–784.
4.
LiJ., LiuK., LiuY.Exosomes mediate the cell-to-cell transmission of IFN-α-induced antiviral activity.Nat Immunol2013; 14: 793–803.
5.
DandriM., LocarniniS.New insight in the pathobiology of hepatitis B virus infection.Gut2012; 61: i6–i17.
6.
HanQ., ZhangC., ZhangJ., TianZ.The role of innate immunity in HBV infection.Semin Immunopathol2013; 35: 23–38.
7.
LoggiE., GamalN., BihlF., BernardiM., AndreoneP.Adaptive response in hepatitis B virus infection.J Viral Hepat2014; 21: 305–313.
8.
MartinetJ., Dufeu-DuchesneT., Bruder CostaJ.Altered functions of plasmacytoid dendritic cells and reduced cytolytic activity of natural killer cells in patients with chronic HBV infection.Gastroenterology2012; 143: 1586–1596.
9.
KondoY., UenoY., ShimosegawaT.Toll-like receptors signaling contributes to immunopathogenesis of HBV infection.Gastroenterol Res Pract2011; 2011: 810939.
10.
StoopJ.N., van der MolenR.G., BaanC.C.Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection.Hepatology2005; 41: 771–778.
11.
XuD., FuJ., JinL.Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B.J Immunol2006; 177: 739–747.
12.
PengG., LiS., WuW., TanX., ChenY., ChenZ.PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients.Mol Immunol2008; 45: 963–970.
13.
FisicaroP., ValdattaC., MassariM.Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B.Gastroenterology2010; 138: 682–693.
14.
RehermannB., NascimbeniM.Immunology of hepatitis B virus and hepatitis C virus infection.Nat Rev Immunol2005; 5: 215–229.
15.
WangF.S., ZhangZ.Host immunity influences disease progression and antiviral efficacy in humans infected with hepatitis B virus.Expert Rev Gastroenterol Hepatol2009; 3: 499–512.
16.
SprengersD., StoopJ.N., BindaR.S.Induction of regulatory T-cells and interleukin-10-producing cells in non-responders to pegylated interferon-alpha therapy for chronic hepatitis B.Antivir Ther2007; 12: 1087–1096.
17.
Aalaei-AndabiliS.H., AlavianS.M.Regulatory T cells are the most important determinant factor of hepatitis B infection prognosis: a systematic review and meta-analysis.Vaccine2012; 30: 5595–5602.
18.
BoniC., PennaA., BertolettiA.Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B.J Hepatol2003; 39: 595–605.
19.
PaceL., VitaleS., DettoriB.APC activation by IFN-alpha decreases regulatory T cell and enhances Th cell functions.J Immunol2010; 184: 5969–5979.
20.
BacherN., RakerV., HofmannC.Interferon-α suppresses cAMP to disarm human regulatory T cells.Cancer Res2013; 73: 5647–5656.
21.
MaoC., WangS., XiaoY.Impairment of regulatory capacity of CD4+CD25+ regulatory T cells mediated by dendritic cell polarization and hyperthyroidism in Graves’ disease.J Immunol2011; 186: 4734–4743.
22.
ChenZ., ChengY., XuY.Expression profiles and function of Toll-like receptors 2 and 4 in peripheral blood mononuclear cells of chronic hepatitis B patients.Clin Immunol2008; 128: 400–408.
23.
VisvanathanK., SkinnerN.A., ThompsonA.J.Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein.Hepatology2007; 45: 102–110.
24.
MiccoL., PeppaD., LoggiE.Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B.J Hepatol2013; 58: 225–233.
25.
HuangY.W., LinS.C., WeiS.C.Reduced Toll-like receptor 3 expression in chronic hepatitis B patients and its restoration by interferon therapy.Antivir Ther2013; 18: 877–884.
26.
HuangY.W., HsuC.K., LinS.C.Reduced Toll-like receptor-9 expression on peripheral CD14+ monocytes of chronic hepatitis B patients and its restoration by effective therapy.Antivir Ther2014; 19: 637–643.
27.
ThompsonA.J., NguyenT., IserD.Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers.Hepatology2010; 51: 1933–1944.
28.
SonneveldM.J., RijckborstV., BoucherC.A.Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline.Hepatology2010; 52: 1251–1257.
29.
MarcellinP., BoninoF., YurdaydinC.Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients.Hepatol Int2013; 7: 88–97.
ChanH.L., ThompsonA., Martinot-PeignouxM.Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report.J Hepatol2011; 55: 1121–1131.
32.
BrunettoM.R., MoriconiF., BoninoF.Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.Hepatology2009; 49: 1141–1150.
33.
ReijndersJ.G., RijckborstV., SonneveldM.J.Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir.J Hepatol2011; 54: 449–454.
34.
ReijndersJ.G., PerquinM.J., ZhangN., HansenB.E., JanssenH.L.Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.Gastroenterology2010; 139: 491–498.
35.
FungJ., LaiC.L., TanakaY.The duration of lamivudine therapy for chronic hepatitis B: cessation vs continuation of treatment after HBeAg seroconversion.Am J Gastroenterol2009; 104: 1940–1946.
36.
ShouvalD., LaiC.L., ChangT.T.Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy.J Hepatol2009; 50: 289–295.
37.
MilichD., LiangT.J.Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection.Hepatology2003; 38: 1075–1086.
38.
HanY., LiJ., JiangL.Regulation of B7-H1 expression on peripheral monocytes and IFN-γ secretion in T lymphocytes by HBeAg.Cell Immunol2013; 283: 25–30.
